Polypeptide With Localisation/Targeting Motif TRIZ Cases

Optimized signal sequences resolve low yield and aggregation by stabilizing disulfide-bonded scFv structures on phage surfaces.

Engineered commensal bacteria produce outer membrane vesicles carrying therapeutic proteins for targeted mucosal delivery.

Anti-podocalyxin antibodies target podocalyxin-mediated metastasis by binding specific tumor epitopes to reduce vascularization.

Placenta-derived allogeneic CAR-T cells expand rapidly to destroy tumor cells while maintaining immune tolerance.

Optimized signal peptides control N-terminal cleavage sites to eliminate heterogeneity and restore functional stability in lambda antibodies.

Engineered peptides featuring histidine and leucine residues enhance cellular permeability while minimizing immunogenicity and toxicity risks.

Replacing IgG hinges with a CD34 spacer eliminates off-target immune activation while enabling efficient cell enrichment.

Chimeric peptides target the ER to stabilize inactive NS3 protease conformations, reducing escape mutant generation in Flaviviridae infections.

A synthetic peptide sequence induces cell reprogramming without gene transduction.

Removing cryptic splice sites and optimizing codons boosts interleukin-15 expression levels by 100-fold while maintaining native amino acid fidelity.

Chimeric antigen receptors with bispecific T cell engagers deliver targeted immune activation to tumors while bypassing blood-brain barrier restrictions.

Metagenomic sequencing identifies CasY endonucleases from uncultivated organisms, expanding CRISPR system diversity without requiring bacterial culture.

Ub-VPAC1 fusion gene vaccine breaks self-tolerance by targeting ubiquitin degradation pathway, enhancing antigen processing to overcome immune suppression.

Peptides disrupt EB3 and IP3R3 interaction, reducing lung vascular leakage in sepsis models.

Multi-chain chimeric polypeptides resolve insufficient immune response by combining tissue factor and IL-15 domains to drive memory-like cell differentiation.

Paired mRNA sequencing isolates tumor-specific antibody sequences from individual immune cells in sentinel lymph nodes.

A chimeric nucleic acid molecule encodes a fusion polypeptide combining a signal peptide, tumor antigen, and heat shock protein to drive immune responses.

Tunable protein assemblies arrange pMHC ligands to activate T cells, resolving the trade-off between cell quantity and immune response reliability.

Ectopic chimeric CD40 on T cells overcomes low clinical response from agonistic antibodies by directly stimulating APCs.

CTPR variant motifs stabilize metal nanoclusters through specific amino acid residues.

Local quality principles guide the insertion of human CD28 into animal genomes, resolving species mismatch issues in tumor microenvironment studies.

A chimeric antigen receptor switch domain modulates immune cell activity via small molecule binding to reduce cytokine-release syndrome.

Integrase-derived peptides stimulate viral cDNA integration into host chromosomal DNA, eradicating infected cells without harming healthy tissue.

Chimeric antigen receptors on T cells target CD33-expressing cancers, resolving the trade-off between treatment effectiveness and targeting specificity.

A chimeric receptor polypeptide triggers conformational changes to activate gene regulation modules.

Secreted blocking proteins retain TCR components in the endoplasmic reticulum, eliminating off-target gene disruptions and graft versus host disease.

Reversibly immobilized multimerization reagents enable controlled T cell expansion while allowing complete agent removal via chromatography.

Truncated N-terminal signal peptide sequence enables high-yield production of functionally active recombinant flavocytochrome b2 in yeast cells.

Marsupial AAV capsid proteins reduce pre-existing immunity in patients while expanding tissue tropism for broader gene therapy applications.